INTRODUCTION
Insulin-dependent diabetes is an organ-specific autoimmune disease resulting from aberrant im-mune response to specific (3-cell autoantigens (1) . Humoral autoimmunity in type I diabetes (IDDM) is generally described in terms of the classic islet-cell antigen (ICA) assay (2) using frozen sections of human pancreas as assay substrate. Serum autoantibodies are detected using a fluorescent second antibody and indirect fluorescence microscopy. Multiple antigens are targets, including glutamic acid decarboxylase (GAD) (3) and the putative protein tyrosine phosphatase 164 Molecular Medicine, Volume 3, Number 3, March 1997 (PTPase) ICA512 (4) . Of new IDDM sera, 28/969 had ICA reactivity but were negative for autoantibodies to GAD, insulin, and ICA512 (W.A. Hagopian, unpublished observation), which suggests that other antigens are also recognized by islet-cell autoantibodies.
Identification of these additional (3-cell antigens could greatly improve IDDM prediction, especially in those patients without a diabetic relative, where most new cases occur. The general population has a low prevalence of IDDM, so high test specificity is critical in achieving predictive values sufficient for clinical immunotherapy. Use of independent, recombinant antigens in radiobinding assays has proven to be highly specific. For example, combining GADab and insulin autoantibodies (IAA) led to a 99.7% specificity (5) . However, only 41% of the subjects were positive for both tests. Adding additional independent antibody tests, and then requiring at least two to be positive, should preserve specificity but improve sensitivity, so that more prediabetics can participate in intervention trials. Identification of (3-cell autoantigens in IDDM also has an important role in potential antigen-based immunointervention therapy. Proposed therapies include vaccination, intravenous monomeric antigen or altered peptide ligands, oral tolerance, and peptide-HLA constructs (6) .
One important but elusive antigen has been the precursor to the 37-kDa tryptic fragment first described by Christie et al. (7) . Although the parent antigen to this tryptic fragment ran as a diffuse band at about 64 kDa on SDS-PAGE, it was distinct from GAD (8) . Presence of autoantibodies to the 37-kDa fragment were shown to be highly predictive of progression to clinical IDDM in both polyendocrine patients (9) and in first-degree relatives of current diabetic patients (10) . The combination of 37-kDa reactivity and GAD reactivity was especially predictive (11, 12) .
To find new (3-cell protein antigens such as the precursor to the 37-kDa antigen, we constructed a highly representative islet cDNA library from pure isolated macaque islets (13) . Unlike rodent islets, they are highly comparable to human islets in antigen expression (13) (16, 17) , also known as IA-2 (18). ICA512 is itself highly recognized by IDDM sera (19) . We here define the structure of M1851, its tissue distribution, antigenic properties, and predictive role in IDDM.
MATERIALS AND METHODS
Highly purified islets were isolated from Macaca nemestrina (pigtail macaque) pancreata by collagenase digestion and density gradient centrifugation as described (13) . Purified mRNA from 105 islets was used to construct a library representative of message at all abundance levels using techniques optimizing synthesis of full-length cDNA (15) . cDNA were ligated into the vector pZCEP (15) The glycerol stock representing one of the positive pools was plated onto agar containing ampicillin. Colonies were probed with 32P-labeled cDNA coding for the intracellular domain of ICA512 obtained by polymerase chain reaction (PCR) from human glioblastoma (18) . Isolated plasmid DNA from a positive colony was sequenced, yielding a sequence similar but not identical to human ICA512 (17, 18) . Using plasmid pools from the original macaque library, a vector-specific upstream primer, and gene-specific antisense primers 5'-CTCTGTGGTCCATGCCTTG C-3' and 5'-GCGCGATGAACTTGGTGGAGTCTT CTTGCTCCGCCTGA-3', the remaining 5' sequence was obtained by the PCR technique termed 5' RACE (rapid amplification of cDNA ends) (21) (Marathon, Clontech, Palo Alto, CA). Using cDNA previously synthesized from human insulinoma mRNA, and primers based on the macaque sequence, 2,456 bases of the human homologue were also amplified by PCR and sequenced.
The second 5' RACE primer above is based on M1851 antisense sequence, just external to the transmembrane region, which is distinct between M1 851 and ICA512. This oligonucleotide probe was radiolabeled with y32P-ATP using T4 polynucleotide kinase (Gibco BRL). Northern analysis of RNA from 23 human tissues distributed over 3 commercially prepared blots (Clontech) each separately hybridized once. Ten milliliters of fresh Express-Hyb buffer (Clontech) containing 5 X 106 cpm/ml of labeled probe was incubated with the blots overnight at 37°C. Blots were then washed with 6X SSC, 0.1% SDS at 25°C, 50°C, and 60°C, and with 2X SSC, 0.05% SDS at 68°C, prior to autoradiography.
The same antisense probe, as well as the corresponding ICA512 antisense probe (5' -AGC TGCCTCCTCCCTCTGTCCCACTCCTGTCTGCAA GA-3') were separately hybridized in situ with 14-,um frozen sections from macaque pancreas, adrenal gland, and muscle. Sections fixed in 4% paraformaldehyde were acetylated with acetic anhydride and delipidated in chloroform prior to use. Probes were end labeled with 33P-dATP (New England Nuclear) using terminal deoxytransferase (Gibco BRL). Probes (2 pmol/ml) were incubated on sections overnight at 450C, washed twice in 1 X SSC at 600C for 30 (5, 22) . Serum samples included 91 healthy control sera (median age 22 years, 51% females), 183 unselected type 1 diabetic patients sampled at onset (median age 11 years, 49% females), and 60 type 1 diabetic patients sampled a mean of 2.0 years before onset (median age 12 years, 42% females). Assay cutoff was an index of 0.04, determined as the mean + 3 standard deviations of indices from the 91 control sera. Sensitivity and predictive value were calculated as described previously (5) . Parallel autoantibody assays used radiolabled icICA512.
To obtain unlabeled icICA512 antigen for competition studies, PCR-generated cDNA sequence for the icICA512 (18) was ligated into the expression vector pZEM219b containing the SV40 promoter (22) and confirmed by sequencing. This vector also constitutively expresses dihydrofolate reductase, allowing methotrexate selection of baby hamster kidney fibroblast transfectants. Cellular icICA512 expression was confirmed by immunocytochemistry (data not shown) using rabbit polyclonal antiserum to ICA5 12.1 (kindly provided by Dr. D. Rabin) (17) . Cells were homognized in 0.2 5% Triton X-114 and 10 mM benzamidine in PBS at pH 7.4. icICA5 12 concentration was estimated at 7 ,ug/ml of cell extract by Western blotting, using as standard recombinant ICA512.1 (kindly provided by Dr. D. Rabin; data not shown). Competition immunoprecipitations used radiolabeled icICA512 per microliter of patient serum. For icM1851 autoantibodies not fully blocked, competitions were repeated at 2.5-fold greater unlabeled icICA512 with no change in results. Extracts from nontransfected fibroblasts had no effect on icM1851 immunoprecipitation.
PCR-amplified sequences based on intracellular M1851 but containing mutations resulting in the deletion of the C-terminal 27, 80, and 160 amino acids (AA) of the 376 AA intracellular domain, were ligated into pcDNAII, radiolabeled during in vitro expression, and used for duplicate immunoprecipitation assays as described above for intact icMI851.
RESULTS
The cloning strategy for M1 851 in macaque and human is shown in Fig. 1A . Starting with the original macaque library M185 1 clone extending from the midextracellular sequence to the 3' end (sequence 1), successive 5' RACE amplifications yielded sequences 3 through 7. A longer clone was also identified by screening the library with one of these products, to obtain confirmatory sequence (sequence 2). Signal peptide, tribasic site, glycosylation site, transmembrane span, PTPase core sequence, stop codon, and poly-A tail are underlined. The partial human sequence was obtained by PCR using gene-specific primers (sequences 9 to 11) and 3' RACE (sequence 8).
The 3,042-nucleotide cDNA sequence and 1,013 residues of primary protein structure of macaque M1851, as well as 2,430 nucleotides and 809 residues of the human sequence, are shown in Fig. lB (Fig. 1C) . Greatest similarity in the extracellular region occurred at the N-terminal 100 residues. In addition to the rat and mouse homologues, Genbank searches revealed greatest homology of M1851 with many protein tyrosine phosphatases, including in decreasing similarity, ICA512 (IA2, PTP35, ICA105, IA2a, pheochromocytoma), liver protein tyrosine phosphatase, and leukocyte common antigen (CD45).
Tissue distribution of M1851 was studied using an oligonucleotide probe based on unique sequence just extracellular to the transmembrane domain. Northern analysis using mRNA from 23 human tissues detected strong 5.5-Kb and weaker 3.3-Kb messages in brain, pancreas, and prostate, with still lesser signals in the spinal cord, thyroid, adrenal, and gastrointestinal (GI) tract (Fig. 2) . To further define tissue localization, in situ hybridization was performed on macaque pancreas, adrenal gland, and muscle (Fig. 3) . Specific signal was demonstrated in pancreatic islets and adrenal medulla, but not muscle. An ICA512 probe and an insulin B-chain probe also hybridized to pancreatic islets, as did the ICA512 probe to adrenal medulla. Unlabeled antisense probes displaced labeled probe binding, treatment of tissue with RNAse A abolished hybridization, and labeled sense oligonucleotides corresponding to each probe showed no hybridization.
The intracellular portion of M1851 was expressed and radiolabeled in vitro in the presence of 35S-methionine. Polyacrylamide gel electrophoresis (PAGE) and autoradiography of the resulting polypeptide revealed a major 46-kDa band and a minor 33-kDa band, both immunoprecipitated by IDDM sera (Fig. 4, left panel) . Limited trypsinization of the immunoprecipitated polypeptide followed by SDS-PAGE and autoradiography revealed a 37-kDa fragment from both macaque and human icM1851. This fragment was distinct from the 40-kDa fragment produced by trypsinization of the 379 AA intracellular domain of human ICA512 (Fig. 4, right panel) .
Immunopreciptation assays using radiolabeled recombinant intracellular M1851 (icMl851) revealed autoantibodies in 56/183 (30.6%) newly diagnosed IDDM patients, 28 
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In order to test whether M 1851 autoantibodies recognized only epitopes shared with ICA512, recombinant icICA512 antigen was expressed in bab.y hamster kidney fibroblasts. Extracts from these fibroblasts fully blocked icM1851 reactivity in 29/53 icMI851-positive sera tested, while a median of 21.4% (range 3-55%) of original immunoreactivity was retained in 24/53 sera (Fig. 6, right panel) . Increasing icICA512 competitor concentration did not reduce this residual immunoreactivity in any of these 24 Mutants containing C-terminal deletions or mutations from the intact 376 AA icM185 1 were constructed by PCR and expressed for immunoassays as above. Removal of the C-terminal 27 residues decreased reactivity by 32% from 19/53 to 13/53 IDDM sera. Importantly, antibody level was also greatly decreased, from a median index among positive sera of 0.49 to a median index of 0.04. Removal of the C-terminal 94 AA decreased reactivity further, to 6/53 IDDM sera (11 %), a 68% decrease from the intact intracellular antigen. Median index decreased to 0.03. Finally, removal of the C-terminal 159 AA abolished all recognition by the 53 IDDM sera. Whether through primary sequence or complex conformational effects, these results emphasize the importance of the far C-terminal region in M1851 autoantibody epitopes.
DISCUSSION
Receptor forms of protein tyrosine phosphatases comprise a large superfamily of enzymes with multiple signaling functions regulating cell growth (23), differentiation (24) , and adhesion (25) family, has a single putative catalytic domain (18) . Like ICA512 and LCA (CD45), M1851 also has an Asp-for-Ala substitution in the active site (26) . The physiological role of these PTPases in the 13-cell remains to be determined, but the rat homologue of M1 851 is associated with insulin secretory granules (26) . Neither 13-cell PTPase has yet been proven to be catalytically active (27) . The tissue distribution of M1 851 is generally neuroendocrine in nature. Northern analysis here showed strong hybridization to human mRNA from brain and pancreas, and weaker hybridization in spinal cord, thyroid, adrenal, and GI tract. In situ hybridization using macaque tissues further localized expression to pancreatic islets and adrenal medulla. Mouse (24) and rat (26) (7) , a large body of evidence is consistent with this conclusion, which has also been reported by others for trypsin-treated human ICA512 (31) and for trypsin-treated mouse (32) and rat (26) homologues of M1851. The 37-kDa and 40-kDa tryptic fragments were described by Christie to derive from a faint 64-kDa band distinct from GAD that was soluble only in 8 M urea (8) . ICA512 and M1851 contain extracellular (intralumenal) dibasic and tribasic residues, respectively, yielding 592 and 588 residue fragments Cterminal to the putative cleavage site, each still containing a hydrophobic transmembrane sequence (18) . These are of the proper size to account for the poorly soluble and diffuse 64-kDa band described by Christie. Christie and co-workers also showed that the 40-kDa and 37-kDa fragment precursors were glycosylated (31) and that they bound to lectins via N-acetyl glucosamine and mannose, respectively. ICA512 and M1851 each have the proper consensus glycosylation site in the extracellular juxtamembrane sequence.
That immunoprecipitation of these two fragments is often parallel (7) is consistent with our findings of (a) common intracellular amino acid sequences, and (b) shared epitopes between the two antigens in most IDDM sera. That the far C terminus is important for M1851 autoreactivity is consistent with structural requirements described for two of four major icICAS12 autoantibody epitopes (33) . Taken together, the data that ICA512 is precipitated by many more sera than M1851, that C-terminal deletions abolish all M1851 reactivity, and that excess ICA512 only partly blocks M1851 reactivity, is consistent with M1851 lacking the juxtamembrane epitope(s) described for ICA512 but containing both unique and shared epitopes at the far C terminus.
Although many candidate ,B-cell autoantigens have been described for IDDM, remarkably few are actually demonstrated targets of the autoimmune response. Insulin autoantibodies (34) have been shown to be highly predictive, especially in combination with ICA and in the very young. T cell responses to human insulin have also been demonstrated (35, 36) . A 64-kDa autoantigen (37) identified as glutamate decarboxylase (GAD) is the target of highly predictive autoantibodies (22) and T cells (35, 38) . The putative protein tyrosine phosphatase ICA512 (16) is also a target of highly predictive antibodies (19) and T cells (35, 36) . Other proposed antigens have been less useful. Carboxypeptidase H antibodies were weakly associated with IDDM (12), ICA69 autoantibodies were not associated with IDDM (12) , Imogen 38 is a mitochondrial protein which was not ,3-cell specific (39) , and Glima 38 reactivity relies on heavy glycosylation and autoantibodies to it were uncommon in diabetes (40) . Antibodies to bovine serum albumin (41) and heat shock protein (42) were nonpredictive in diabetes. The 105-kDa RIN antigen (43) and 52-kDa rubella-associated antigen (44) remain elusive, and predictivity has not been confirmed. Data on the reactivity of sulfatides (45) and gangliosides (46) remain limited since these nonprotein antigens are not easily used in immunoassays. That M1851 autoantibodies are prevalent in diabetes and prediabetes and that M1851 contains unique autoantibody epitopes not present on ICA512, suggest that this is a new IDDM autoantigen. Given the limited (77%) amino acid identity in the intracellular domain, unique T cell epitopes are also possible.
The utility of M1851 autoantibodies in the screening and prediction of IDDM may be limited, since ICA512ab had greater sensitivity whereas only 0.7% of patients not detected by ICA512ab had M1851ab. Like ICA512ab, M1851 autoantibodies are most prevalent near disease onset, which suggests that M1851 is not primary in IDDM pathogenesis. Nevertheless, T lymphocyte help is required to form the high-affinity precipitating autoantibodies we have described. Cellular immunity developing late in prediabetes may be important, for example, in /-cell killing which has been suggested to occur primarily late in the pathogenesis (47) .
Therapies based on such antigens involved late in the pathogenesis may be especially relevant in treating older IDDM patients identified by autoantibody testing at the time of clinical NIDDM diagnosis (22) . These late onset IDDM patients are nearly as numerous as classical childhood IDDM (22, 48) . Late immuno-intervention therapy in these patients may be especially effective (49, 50) perhaps because of the slowly progressive nature of their f-cell destruction. Given the high specificity of HLA-peptide interactions, differences in protein sequence between even homologous domains of ICA512 and Ml 851 could lead to different T cell activation by these molecules. Efforts to develop peptides (51) and peptide HLA conjugates (52) for immunotherapy require use of specific amino acid sequences from these or other ,3-cell autoantigens.
The presence of unique autoantibody epitopes on M1851, and its general neuroendocIine tissue expression, support M1851 as a new islet autoantigen in IDDM. Its dual roles as a /3-cell insulin secretory granule protein and as a target of the autoimmune response in prediabetes may provide important insights into /3-cell physiology as well as the pathogenesis and therapy of autoimmune diabetes.
